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Abstract
Aims—We sought to determine characteristics which strengthen the association between markers 
of diabetic kidney disease and retinopathy.
Methods—Multivariate regression analyses of NHANES 2005–2008 assessed the association of 
retinopathy with renal insufficiency and albuminuria. Analyses were stratified to evaluate 
ethnicity/race, obesity, and use of renin–angiotensin–aldosterone system antagonists as effect 
modifiers of this relationship.
Results—Of 269 participants with renal insufficiency, 35% had no microalbuminuria and no 
retinopathy; 16.1% had retinopathy with no microalbuminuria; 27.1% had microalbuminuria and 
no retinopathy and 22% had both microalbuminuria and retinopathy. Stratified, multivariate 
logistic regression analyses demonstrated retinopathy to be significantly predictive of renal 
insufficiency only in nonHispanic Blacks (OR = 2.7; 95% CI 1.2, 6.1), obesity (OR = 2.6; 95% CI 
1.3, 5.5) and in those participants not using renin–angiotensin–aldosterone blockers (OR = 2.5; 
95% CI 1.1, 5.7). Analyses showed an independent relationship between retinopathy and 
albuminuria only when albuminuria was modeled continuously.
Conclusions—In older onset diabetes, the absence of albuminuria and retinopathy is common 
among individuals with renal insufficiency. The relationship between microvascular complications 
of the eye and kidney may vary according to ethnicity, obesity and use of renin– angiotensin–
aldosterone antagonists. These findings need to be confirmed in other large, diverse cohorts.
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1. Introduction
The rising prevalence of type 2 diabetes has increased the likelihood of microvascular 
complications [1,2]. In the United States (U.S.) alone, 24,000 people develop blindness and 
more than 45,000 people begin dialysis each year as the result of diabetes [2,3]. Yet, 
establishing a diagnosis of diabetic kidney disease often poses a clinical challenge among 
individuals with type 2 diabetes. Decreased glomerular filtration rate in the presence of 
systemic microvascular complications are commonly used to estimate diabetic nephropathy. 
While retinopathy and nephropathy are postulated to have similar pathogenic mechanisms 
[4], the correlation is stronger in type 1 than type 2 diabetes [5,6]. Up to one-third of 
individuals with type 2 diabetes and decreased estimated glomerular filtration rate (eGFR) 
have an absence of albuminuria [7,8]. This subgroup also tends to have lesser degrees of 
retinopathy than those with albuminuria, leading many to postulate that this population has a 
predominance of hypertensive and/or renal vascular disease rather than classical diabetic 
glomerulosclerosis [9].
In people with type 2 diabetes, the risk of developing microvascular complications is 
increased with obesity [10]. Ethnic minorities also have an increased risk of severe and 
progressive retinopathy and nephropathy [11–13]. Moreover, the strength of association 
between retinopathy and nephropathy has been noted to be greater in Latinos than 
nonHispanic Whites [14]. Examination of individual-level characteristics that modify the 
relationship between diabetic retinopathy and nephropathy, may assist in the clinical 
evaluation of diabetic kidney disease, as well as to further elucidate the underlying 
pathogenesis of microvascular complications. To the best of our knowledge the strength of 
this association has not been examined in nonHispanic Blacks and among individuals with 
significant obesity. It is also unknown whether antagonists of the renin–angiotensin–
aldosterone system (RAAS) alters the renal–retinal relationship. The purpose of the present 
study is to characterize the effect of ethnicity, body mass index (BMI) and RAAS 
antagonists on the relationship between retinopathy and decreased eGFR or albuminuria in 
older onset diabetes, using a nationally representative sample of the U.S. population.
2. Subjects materials and methods
2.1. Study population
The National Health and Nutrition Examination Survey (NHANES) is a nationally 
representative sample of the total US civilian, non-institutionalized population. It uses a 
stratified, multistage probability design with planned oversampling of certain age and racial/
ethnic groups. NHANES (2005–2008) included 7081 individuals with complete 
sociodemographic information and data from physical examination. The NHANES protocol 
was approved by a human subjects review board and written, informed consent was obtained 
from all participants.
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2.2. Definition of type 2 diabetes
Diabetes was self-reported as being previously diagnosed by a physician (except during 
pregnancy) or as current or past use of insulin or oral agents. Diabetes type was not 
available. We excluded 66 individuals who reported the diagnosis of diabetes prior to age 30, 
as these individuals likely had type 1 diabetes. Adults who completed the physical 
examination and had fasted appropriately, had fasting serum glucose measured and 
underwent a 75 g oral glucose challenge test. Newly diagnosed diabetes was defined as a 
fasting glucose ≥6.99 mmol/L (126 mg/dL) or a 2 h post glucose challenge of ≥11.1 mmol/L 
(200 mg/dL).
2.3. Fundus photography
NHANES 2005–2008 used the Canon CR6-45NM ophthalmic digital imaging system and 
Canon EOS 10D digital camera (Canon, Tokyo, Japan) to take 2 digital images per eye 
through a nonpharmacologically dilated pupil. Participants were seated in a windowless 
room with the lights turned off to allow for nonpharmacological pupillary dilation. One 
retinal image was centered on the macula and the second image was centered on the optic 
disc. The digital images were graded using a modification of the Airlie House classification 
scheme of diabetic retinopathy at the University of Wisconsin Ocular Epidemiologic 
Reading Center (Madison, WI). Capture and grading of digital images and quality of control 
by the Wisconsin group have been described in detail previously [15]. In brief, for each eye 
the maximum grade in any of the seven standard photographic fields was determined for 
each of the lesions. If the retinopathy severity could not be graded in an eye, it was 
considered to have a score equivalent to that in the other eye. Retinopathy severity was 
categorized into four levels: none, mild nonproliferative diabetic retinopathy, moderate to 
severe nonproliferative diabetic retinopathy and proliferative retinopathy. The retinopathy 
grade based on the more advanced eye was used for analyses [16].
2.4. Albuminuria measurements
A single, random urine collection was obtained for urine albumin:creatinine ratio (UACR). 
Urinary albumin was quantified using solid-phase fluorescent immunoassay. Urinary 
creatinine was measured with the Jaffe rate reaction. Micro-albuminuria was defined as a 
UACR of 3.4–33.8 mg/mmol (30–299 µg/mg) and macroalbuminuria as ≥33.9 mg/mmol 
(300ug/ mg). Where albuminuria is analyzed as a bivariate variable, 3.4 mg/mmol (30 
µg/mg) was used as a threshold cut-point.
2.5. Estimation of GFR
GFR was estimated using the 6-variable Modification of Diet in Renal Disease (MDRD) 
equation, as follows:
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Serum creatinine was measured using the modified kinetic reaction of Jaffe. We defined low 
eGFR as less than 60 ml/min/1.73 m2.
2.6. Covariate measurements
Age was defined as the age at the time of the examination. Race and ethnicity were self 
reported as Non-Hispanic White, Non-Hispanic Black, Mexican American and all others 
were grouped as ‘Other’. The latter group was excluded from the stratified analyses by 
ethnicity due to the very low number of participants in this category. Blood pressure was 
defined as the mean of six separate readings. BMI was calculated from the weight and height 
measurements taken during the physical examination. Hemoglobin A1c (HbA1c) was 
measured by a high performance liquid chromatographic assay. Individuals taking an 
angiotensin converting enzyme inhibitor or angiotensin receptor blocker or aldosterone 
receptor blocker were categorized as being on a RAAS antagonist.
2.7. Statistical methods
All analyses were performed using Stata (version 11), and SPSS (version 16) statistical 
software. Two-sided hypotheses and tests were adopted for all statistical inference. 
NHANES is a complex probability sample, so we used appropriate sample weights to 
estimate mean values and standard errors [17]. To combine data from two 2-year cycles of 
the continuous NHANES (2005–2006 and 2007–2008), we created new sample weights.
We used univariate logistic regression models between independent variables and low eGFR 
to calculate odds ratios and 95% confidence intervals. The same analyses were performed 
with albuminuria as a bivariate dependent variable as well as an ordinal variable (normal–
micro–macro). Multivariate regression analyses were performed to further assess the 
relationship between retinopathy and low eGFR as well as between retinopathy and 
albuminuria. Covariates included age, gender, HbA1c, systolic and diastolic blood pressures. 
Univariate logistic regression was used to evaluate the significance of the interactions: 
retinopathy × ethnicity and retinopathy × BMI and retinopathy × RAAS antagonist. 
Significance of the interaction terms led to stratified analyses. Significance was defined by a 
p-value < 0.05.
3. Results
The participants from NHANES 2005–2008 with data available for analysis are depicted in 
Fig. 1. There were 1108 participants who self-reported being previously diagnosed with 
diabetes, 512 participants with a fasting glucose ≥6.99 mmol/L (126 mg/ dl) and 248 
participants who had an OGTT ≥11.1 mmol/L (200 mg/dl). Individuals reporting diabetes 
diagnosed prior to the age of 30 years were felt likely to have type 1 diabetes and hence 
were excluded (n = 66). An additional 140 individuals were excluded from eGFR analyses 
due to lack of available serum creatinine data. In analyses of albuminuria, 115 individuals 
were excluded due to lack of available UACR data. In total, there were 1292 participants 
with older onset diabetes available for eGFR analyses and 1317 for albuminuria analyses.
Decreased eGFR, defined as less than 60 ml/min/1.73 m2, was present in 18%; 
microalbuminuria in 26% and macro-albuminuria in 9% of participants with adult onset 
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diabetes. Of 269 participants with decreased eGFR and available UACR data, 35% had no 
microalbuminuria and no retinopathy; 16.1% had retinopathy with no microalbuminuria; 
27.1% had microalbuminuria and no retinopathy and 22% had both microalbuminuria and 
retinopathy. Fig. 1 displays the weighted U.S. population estimates for these statistics.
Characteristics of participants with later onset diabetes with decreased versus ‘normal’ 
eGFR are displayed in Table 1. Those with decreased eGFR tended to be older, had a higher 
pulse pressure and more commonly had a history of retinopathy and/or cardiovascular 
disease compared to those with normal eGFR. The presence of any retinopathy was 
associated with a two-fold increased odds ratio of decreased eGFR. The presence of 
proliferative retinopathy was associated with a 7-fold increased odds ratio of low eGFR. The 
frequency of decreased eGFR was similar in nonHispanic whites and nonHispanic Blacks 
but was lower in Latinos.
The univariate interaction terms, retinopathy × ethnicity, retinopathy × obesity and 
retinopathy × RAAS antagonist were all significant (p < 0.05). Multivariate logistic 
regression analyses stratified by ethnicity showed a significant association of retinopathy 
with decreased eGFR in nonHispanic Blacks but not nonHispanic Whites or Latinos (Fig. 
2a). Multivariate logistic regression analyses stratified by BMI ≥30 kg/m2 versus <30 kg/m2 
showed retinopathy to be significantly associated with decreased eGFR in obese but not 
nonobese individuals (Fig. 2b). Similarly, the stratified analyses by use of a RAAS 
antagonist demonstrated a significant relationship between retinopathy and low eGFR only 
in those who were not on a RAAS inhibitor (Fig. 2c). We explored the possibility that 
ethnicity and BMI could confound one another by including both terms in the analyses and 
the results were not changed (data not shown).
Similar analyses of albuminuria categorized as normal, micro- or macro- did not reveal any 
differences with regard to covariates including age, ethnicity, retinopathy, BMI, HbA1c or 
systolic/diastolic blood pressure (Table 2). Univariate, ordinal logistic regression 
demonstrated a 1.8-fold risk of albuminuria with any retinopathy and a 2.7-fold risk for 
mod-severe retinopathy. There was also an increased risk of albuminuria with a history of 
cardiovascular events (OR = 2.4 and 95% CI 1.6, 3.5). Multivariate logistic regression 
analyses of retinopathy and albuminuria (both bivariate and ordinal) were not significant. 
Recategorization of retinopathy by severity did not change these results. Modeling of 
albuminuria in a continuous fashion did detect a significant association (p < 0.001). 
Univariate analysis of interaction between retinopathy and ethnicity, obesity and RAAS 
inhibitor use were all nonsignificant.
4. Discussion
In this analysis of a nationally representative U.S. population of people with older onset 
diabetes, we confirmed the independent association between retinopathy and decreased 
eGFR but not albuminuria [5,6,18]. The association between retinopathy and low eGFR < 60 
ml/min/1.73 m2 was stronger in nonHispanic black, obese populations and individuals who 
are not taking a RAAS antagonist. Approximately one-third of individuals with older onset 
diabetes and decreased eGFR had neither albuminuria nor retinopathy.
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We examined ethnicity, obesity and RAAS antagonist use as effect modifiers of the renal–
retinal relationship because we hypothesized that these populations were more likely to have 
‘typical’ diabetic glomerulosclerosis. Obesity was examined as an effect modifier due to the 
fact that the risk of diabetic microvascular disease is increased in those with concurrent 
metabolic syndrome [10,19]. Moreover, obesity and metabolic syndrome are known to result 
in increased inflammatory mediators known to be relevant to microangiopathies [20,21].
Ethnic minorities have a significantly higher risk of both diabetic retinopathy and 
nephropathy, likely due to increased risk factors and possibly an underlying genetic 
susceptibility [11,13,22,23]. We did not find an increased association in Latino individuals 
as has been cited by others [14], likely due to the small sample size of this ethnic group. The 
heavily overlapping confidence intervals between nonHispanic Whites and Blacks 
underscore the possibility that the discrepancy between these ethnic groups could be due to 
mediation of the effect by covariates included in the analysis. Alternatively, our finding 
could be due to chance. However, it is equally possible that the discrepancy between 
ethnicities could be even greater than that found in this analysis, especially as the confidence 
interval in the nonHispanic Black population are skewed toward higher odds ratios. The 
wide confidence intervals in the nonHispanic Black stratum were partly due to sample size 
limitations that could not be avoided. Our finding of a discrepancy in the strength of 
association between retinopathy and low eGFR is merely suggestive, but does warrant 
further investigation.
We detected an association between retinopathy and albuminuria only when UACR was 
modeled in a continuous fashion, likely due to increased power of this approach. 
Historically, categorical and ordinal classification of albuminuria has yielded an association 
with retinopathy in diabetes [18,24,25]. The reason for our disparate results is unclear, but 
could be due to a number of factors including sample size, population characteristics or a 
shift away from albuminuria in this age of maximal blockade of the RAAS. Our findings are 
particularly relevant, given that epidemiologic studies have demonstrated over the last 
decade that microalbuminuria does not carry the same prognostic value in diabetic kidney 
disease as once thought. Albuminuria regresses more often than it progresses, and is often 
absent despite a decline in eGFR [7,8,26,27].
The strength of association between retinopathy and diabetic kidney disease likely varies 
depending on the duration of disease and whether nephropathy is being analyzed with 
respect to histologic measurements versus albuminuria versus eGFR. In a Caucasian 
population with type 1 diabetes and normoalbuminuria and normal or elevated eGFR, there 
was a strong association of retinopathy severity and histologic indicators of basement 
membrane thickness and mesangial expansion [16]. Nephropathologic study of type 2 
diabetics with nephrotic range proteinuria show those with Kimmelstiel Wilson nodules tend 
to have significantly worse retinopathy than those with solely mesangioproliferative lesions 
[28].
Analysis of an Italian population with type 2 diabetes and microalbuminuria found more 
severe retinopathy in those with ‘classical’ diabetic glomerulosclerosis versus those with 
mostly tubulointerstitial lesions and vasculopathy [29]. We hypothesize that the stronger 
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association between retinopathy and nephropathy occurs in those with ‘typical’ diabetic 
glomerulosclerosis. The emergence of nonproteinuric diabetic kidney disease and reduced 
association between retinopathy and kidney disease in type 2 diabetes could be due to a rise 
in the prevalence of renal vascular disease. The role of kidney biopsy may grow in 
importance to accurately define histopathology in people with type 2 diabetes. Furthermore, 
the histologic phenotype of diabetic kidney disease could aide in the design of future clinical 
trials where investigational drugs for diabetic kidney disease would be targeted to patient 
populations with a predominance of classical or other histologic phenotype.
Limitations to the present study include its exclusion of institutionalized individuals who 
likely have higher rates of diabetic complications, inability to definitively distinguish 
between type 1 and type 2 diabetes, and exclusion of a substantial number of individuals 
who did not have available serum creatinine, UACR or retinal fundus photographs. Survey 
participants who had no light perception or severe visual impairment in both eyes, or a 
severe infection in 1 or both eyes were also excluded. Albuminuria was assessed using a 
single random urine collection which tends to be less robust than first morning urine 
specimen. A true diagnosis of microalbuminuria requires two out of three positive specimens 
and hence we cannot rule out the possibility of misclassification. We did not include 
duration of diabetes in multivariate analyses because this information was missing in the 
majority of participants.
It is noted that use of odds ratios has the potential to overestimate the effect size, especially 
in the setting of relatively common outcomes and in small to moderate sample sizes [30]. 
With respect to the interaction between ethnicity and retinopathy, there is a notable overlap 
in the 95% confidence intervals between blacks and whites. It is possible that the finding of 
this interaction is due to chance. We feel this is unlikely, however, given our a priori 
hypothesis about ethnicity as a modifier based on the existing evidence for more severe 
disease in Blacks [11–13,23]. It is likely that the overlap in confidence intervals is due to the 
limited sample size and use of self-report to categorize ethnicity.
Strengths of the study include the ethnically diverse, population-based national sample and 
assessment of diabetic retinopathy with bilateral digital retinal images using a standardized 
grading scheme. We used unbiased diagnostic criteria for diabetes, including those who were 
previously undiagnosed. Lastly, we examined the association between diabetic retinopathy 
and kidney disease using both eGFR and albuminuria measurements.
In conclusion, we found an increased association of diabetic retinopathy and decreased 
eGFR in nonHispanic black and obese populations and in those who were not on a RAAS 
blocking agent. We hypothesize that this may be due to a higher prevalence of true diabetic 
glomerulosclerosis in these populations as opposed to diabetic renal vascular disease. We 
suggest that research protocol kidney biopsies may help to elucidate the spectrum of renal 
microvascular disease in people with type 2 diabetes in this era of optimal diabetes and 
blood pressure control.
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Flow Chart of selection criteria for analysis of retinopathy and markers of kidney disease in 
type 2 diabetics: NHANES 2005–2008. Percentages are weighted for the distribution of the 
U.S. population.
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Multivariate logistic regression analysis of the relationship between retinopathy and 
decreased eGFR < 60 ml/min/1.73 m2 stratified by (a) ethnicity and (b) body mass index and 
(c) use of RAAS antagonist. Analyses were adjusted for the following covariates: age, 
gender, HbA1C, systolic blood pressure and diastolic blood pressure.
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Table 1
Clinical characteristics of older onset diabetic participants according to estimated glomerular filtration rate 
(eGFR) ≥ or < 60 ml/min/1.73 m2: NHANES 2005–2008.
Characteristics eGFR ≥60 ml/min/1.73 m2
(95% CI) n = 1023
eGFR < 60 ml/min/1.73 m2
(95% CI) n = 269
Odds ratio
(95% CI)
Age (years) 60.4 (59.2–61.6) 72 (70–73) 1.1 (1.07–1.1)*
Female gender (%) 49 (45–54) 60 (53–67) 1.5 (1.1–2.2)
Non-hispanic white (%) 66 (59–74) 77 (70–84) 1.0
Non-hispanic black (%) 15 (11–19) 14 (9–19) 0.8 (0.6–1.2)
Latino (%) 13 (9–17) 6 (3–9) 0.4 (0.3–0.6)*
Other ethnicity (%) 6 (3–8) 3 (1–5) 0.4 (0.2–1.1)
Retinopathy any (%) 24 (20–27) 39 (29–48) 2.0 (1.3–3.1)
None (%) 76 (73–80) 61 (52–71) 1.0
Mild (%) 18 (15–21) 26 (19–33) 1.8 (1.1–2.8)
Moderate–severe (%) 5 (3–7) 9 (2–15) 2.1 (0.96–4.8)
Proliferative (%) 0.7 (0.3–1.0) 4 (3–5) 7.1 (3.8–13.0)*
History of CV event (%) 24 (21–28) 52 (45–59) 3.4 (2.5–4.5)*
Body mass index (kg/m2) 32 (32–33) 32.6 (31–34) 1.0 (1.0–1.0)
BMI ≥30 (%) 57 57 1.0 (1.0–1.0)
HbA1C (%)
(mmol/mol)
6.9 (6.8–7.0) 6.8 (6.5–7.0) 0.9 (0.8–1.1)
52 (51–53) 51 (48–53)
SBP (mmHg) 131 (129–133) 140 (134–143) 1.0 (1.0–1.0)*
DBP (mmHg) 70 (69–71) 61.3 (59–63) 1.0 (1.0–1.0)*
Pulse pressure (mmHg) 61 (59–63) 79 (76–81) 1.0 (1.0–1.0)*
Use of RAAS blockers (%) 42 (36–48) 58 (52–64) 1.4 (1.5–2.9)
CV = cardiovascular; SBP = systolic blood pressure; DBP = diastolic blood pressure; RAAS = renin–angiotensin–aldosterone system.
*
p < 0.001.
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Table 2
Clinical characteristics of older onset diabetic participants according to status of albuminuria: NHANES 
2005–2008.
Characteristics Normoalbuminuria
(95% CI) n = 864
Microalbuminuriaa
(95% CI) n = 340
Macroalbuminuriab
(95% CI) n = 113
Odds ratio
(95% CI)
Age (years) 60.5 (59.2–61.9) 63.7 (61.4–66.0) 63.2 (59.5–66.8) 1.0 (1.0–1.0)
Female gender (%) 51 (47–56) 53 (45–60) 49 (35–63) 1.01 (0.8–1.4)
Non-hispanic white (%) 68 (61–76) 66 (58–75) 53 (36–69) 1.0
Non-hispanic black (%) 15 (10–19) 15 (10–20) 24 (15–33) 1.3 (0.9–1.9)
Latino (%) 12 (8–16) 14 (9–20) 11 (4–18) 1.2 (0.9–1.7)
Other ethnicity (%) 5 (2–8) 4 (1–8) 12 (3–21) 1.5 (0.7–3.3)
Retinopathy any (%) 23 (19–27) 27 (20–34) 54 (42–66) 1.8 (1.1–2.8)
None (%) 77 (73–81) 73 (66–80) 46 (34–58) 1.0
Mild (%) 18 (15–22) 20 (14–26) 33 (18–48) 1.5 (0.9–2.5)
Moderate–severe (%) 4 (2–6) 6 (2–10) 17 (7–28) 2.7 (1.4–5.5)§
Proliferative, (%) 1 (0–2) 0 (0–2) 4 (0–7) 3.1 (0.7–12.9)
History of CV event (%) 23 (19–27) 39 (32–47) 46 (34–59) 2.4 (1.6–3.5)§
Body mass index (kg/m2) 32 (32–33) 32 (30–33) 33 (31–35) 1.0 (1.0–1.0)
HbA1C (%)
(mmol/mol)
6.8 (6.6–7.0) 7.0 (6.8–7.3) 7.4 (7–7.9) 1.1 (1.0–1.3)
51 (49–53) 53 (51–56) 57 (53–63)
SBP (mmHg) 129 (127–130) 138 (135–140) 150 (145–156) 1.0 (1.0–1.0)§
DBP (mmHg) 69 (68–70) 68 (66–71) 70 (63–78) 1.0 (1.0–1.0)
Pulse pressure (mmHg) 60 (58–62) 69 (66–73) 80 (72–87) 1.0 (1.0–1.0)§
RAAS blockers (%) 41 (36–46) 48 (43–53) 53 (42–64) 1.4 (1.0–1.9)
CV = cardiovascular; SBP = systolic blood pressure; DBP = diastolic blood pressure; RAAS = renin–angiotensin–aldosterone system.
a
Microalbuminuria defined as urine albumin:creatinine ratio (UACR) 3.4–33.8 mg/mmol (30–299 µg/mg).
b
Macroalbuminuria defined as UACR ≥33.9 mg/mmol (300 µg/mg).
§
p < 0.001.
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